About the Novel Therapeutics for Bleeding Disorders (NoT Bleeding) Program
Given Children's Hospital of Philadelphia’s (CHOP) longstanding leadership in developing gene therapy for hemophilia, expertise in the molecular basis of coagulation, and extensive clinical experience, the NoT Bleeding Program is uniquely positioned to counsel patients on choosing the appropriate treatment strategy for each individual’s case and hemostatic physiology.
The clinic will provide state-of-the-art individualized treatment plans for patients with hemophilia and rare blood disorders to assist patients, families and referring physicians to choose the best available therapy for each patients.
The clinic will bring together clinicians and translational scientists to review each case and recommend an optimal treatment course based upon the patient’s history, response to prior therapies, available trials and understanding of the molecular basis of the disease.
The NoT Bleeding clinic is composed of a variety of healthcare professionals. Dedicated nurses help patients navigate referrals, appointment scheduling, insurance and coordinated care. Social workers are available to assist with a wide range of patient concerns, and genetic counselors provide education and support related to genetic causes of bleeding disorders. Financial counselors help patients manage any financial considerations related to their care including for gene therapy.